Macrogenics (MGNX) Research & Development (2012 - 2026)
Macrogenics (MGNX) posted quarterly Research & Development of $35.0 million for Q1 2026, down 11.9% year-over-year from $39.7 million in Q1 2025, and up 2.94% quarter-over-quarter from $34.0 million in Q4 2025.
Macrogenics (MGNX) Research & Development (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Research & Development for 15 consecutive years, with $35.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 11.9% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $142.4 million (down 16.63% YoY), while the FY2025 annual figure was $147.2 million, down 16.94% from the prior year.
- Research & Development improved to $35.0 million in Q1 2026 per MGNX's latest filing, from $34.0 million in the prior quarter.
- Across five years, Research & Development topped out at $61.4 million in Q1 2022 and bottomed at $30.1 million in Q3 2023.
- Historically, Research & Development has averaged $43.1 million across 5 years, with a median of $43.2 million in 2023.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 37.48% — and 2024, when it jumped 34.56%.
- Macrogenics' Research & Development stood at $45.7 million in 2022, then climbed by 3.72% to $47.4 million in 2023, then dropped by 17.87% to $38.9 million in 2024, then slipped by 12.64% to $34.0 million in 2025, then climbed by 2.94% to $35.0 million in 2026.
- Business Quant data shows MGNX's Research & Development at $35.0 million in Q1 2026, $34.0 million in Q4 2025, and $32.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 34.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.97 Mn |
| Dec 31, 2025 | 33.97 Mn |
| Sep 30, 2025 | 32.71 Mn |
| Jun 30, 2025 | 40.79 Mn |
| Mar 31, 2025 | 39.70 Mn |
| Dec 31, 2024 | 38.89 Mn |
| Sep 30, 2024 | 40.54 Mn |
| Jun 30, 2024 | 51.73 Mn |
| Mar 31, 2024 | 46.03 Mn |
| Dec 31, 2023 | 47.35 Mn |
| Sep 30, 2023 | 30.13 Mn |
| Jun 30, 2023 | 43.23 Mn |
| Mar 31, 2023 | 45.87 Mn |
| Dec 31, 2022 | 45.65 Mn |
| Sep 30, 2022 | 48.19 Mn |
| Jun 30, 2022 | 51.74 Mn |
| Mar 31, 2022 | 61.44 Mn |
| Dec 31, 2021 | 55.85 Mn |
| Sep 30, 2021 | 49.82 Mn |
| Jun 30, 2021 | 55.78 Mn |